GENE-THERAPEUTIC DNA-VECTOR BASED ON THE GENE-THERAPEUTIC DNA-VECTOR VTVAF17, CARRYING THE TARGET GENE SELECTED FROM A GROUP OF GENES BDNF, VEGFA, BFGF, NGF, GDNF, NT3, CNTF, IGF1, TO INCREASE EXPRESSION LEVEL OF SAID TARGET GENES, METHOD FOR PRODUCTION AND USE THEREOF, A STRAIN ESCHERICHIA COLI SCS110-AF/VTVAF17-BDNF, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-VEGFA, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-BFGF, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-NGF, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-GDNF, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-NT3, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-CNTF, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-IGF1, CARRYING A GENE-THERAPEUTIC DNA VECTOR, METHOD FOR PRODUCTION THEREOF, A METHOD FOR INDUSTRIAL PRODUCTION OF A GENE-THERAPEUTIC DNA VECTOR

摘要

FIELD: genetic engineering.;SUBSTANCE: invention can be used in biotechnology, medicine and agriculture for creation of gene therapy preparations. Disclosed is a gene-therapeutic DNA vector based on the VTvaf17 gene-vector DNA vector carrying the target gene, selected from a group of genes to increase the level of expression of this target gene in the human body and animals. Genotyping DNA vector VTvaf17-BDNF, or VTvaf17-VEGFA, or VTvaf17-BFGF, or VTvaf17-NGF, or VTvaf17-GDNF, or VTvaf17-NT3, or VTvaf17-CNTF, or VTvaf17-IGF1 has a nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, or SEQ ID No. 5, or SEQ ID No. 6, or SEQ ID No. 7, or SEQ ID No. 8, respectively. Also disclosed are a method of producing said vector, using a vector to increase the level of expression of target genes, an Escherichia coli strain carrying said vector, as well as a method for production of said vector on an industrial scale.;EFFECT: invention provides the possibility of its safe application for genetic therapy of humans and animals.;22 cl, 23 dwg, 32 ex